| Prev Close | 643.35 |
| Day Low/High | 642.41 / 660.50 |
| 52 Wk Low/High | 441.00 / 686.62 |
Regeneron Pharmaceuticals, Inc. (REGN)
654.40
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 107.57B |
| Market Cap | 69.20B |
| P/E Ratio | 19.71 |
| Div & Yield | N.A. (N.A) |
The Magic Mice of Regeneron
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work
The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.
5 Leading Biotechs in Search of a Coronavirus Vaccine
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
This Stock Is Standing Up to the Correction Like Few Others
Biotech name has bolted higher with some amazing relative strength.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity
The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.
Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal
Are the technical and quantitative approaches on the same page?
RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
Real Money Post Industrial Average Exits October on Top
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
Real Money Post-Industrial Average Continues to Outpace Major Indices
RMPIA is up 20.9% in the first nine months of 2019.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
2 Well-Known Stocks You Should Consider Shorting This Week
These bearish bets are showing both technical and quantitative deterioration.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
A Bullish Play on Netflix
Netflix is bullish, but faces key resistance before it can make a big run higher.
Stalking an Entry in Regeneron Pharmaceuticals
A low-risk countertrend options trade may be worth a look in this name.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
2 Well-Known Stocks to Consider Shorting Thanksgiving Week
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Regeneron Soars After My 'Go Long' Recommendation: What Now?
An updated strategy for the high-flying REGN.
Regeneron Is Leading the Way for Biotech
Recent action tells us REGN's momentum is super strong.
